Atreca, Inc. (BCEL)
Atreca, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing antibody-based immunotherapeutics for solid tumors. Their lead product candidate, ATRC-101, targets a novel mechanism of action derived from their proprietary discovery platform.
Company Overview
Atreca, Inc. pioneers antibody-based cancer immunotherapies, leveraging its innovative discovery platform to develop ATRC-101, a promising monoclonal antibody targeting a broad range of solid tumors, positioning the company for significant growth in the biotechnology sector.
Investment Thesis
Atreca presents a compelling investment opportunity due to its innovative antibody discovery platform and promising lead candidate, ATRC-101. The company's focus on solid tumors, a significant unmet medical need, positions it for substantial growth if ATRC-101 demonstrates clinical efficacy. Key value drivers include the successful advancement of ATRC-101 through clinical trials, potential partnerships for further development and commercialization, and the expansion of its pipeline with novel antibody-based immunotherapeutics. The collaboration with Xencor and the Bill & Melinda Gates Medical Research Institute further validates Atreca's technology and provides access to additional resources and expertise. With a market capitalization of $0.00B and a negative P/E ratio of -0.04, Atreca is a high-risk, high-reward investment opportunity.
Key Highlights
- Lead product candidate ATRC-101 demonstrates in vitro reactivity with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples.
- Collaboration with Xencor, Inc. for the development and commercialization of novel CD3 bispecific antibodies in oncology.
- Licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria.
- Gross Margin of -819.6% indicates significant investment in research and development.
- Profit Margin of -12617.8% reflects the company's current stage as a clinical-stage biopharmaceutical company with no products yet generating revenue.
Competitors
Strengths
- Proprietary antibody discovery platform.
- Novel mechanism of action of ATRC-101.
- Strategic collaborations with Xencor and the Bill & Melinda Gates Medical Research Institute.
- Focus on a significant unmet medical need (solid tumors).
Weaknesses
- Clinical-stage company with no products currently generating revenue.
- High research and development costs.
- Dependence on the success of ATRC-101.
- Negative gross and profit margins.
Catalysts
- Upcoming: Data readouts from ongoing clinical trials of ATRC-101.
- Ongoing: Advancement of other product candidates through preclinical and clinical development.
- Ongoing: Potential for new strategic partnerships and collaborations.
Risks
- Potential: Clinical trial failures for ATRC-101 or other product candidates.
- Potential: Regulatory delays or rejection of product candidates.
- Ongoing: Competition from other biotechnology and pharmaceutical companies.
- Potential: Patent challenges to Atreca's intellectual property.
- Ongoing: High cash burn rate and need for additional financing.
Growth Opportunities
- Advancement of ATRC-101 through clinical trials: The successful completion of clinical trials for ATRC-101 represents a significant growth opportunity for Atreca. Positive clinical data could lead to regulatory approval and commercialization, potentially generating substantial revenue. The market for solid tumor therapies is estimated to be worth billions of dollars, offering a significant upside for Atreca if ATRC-101 proves to be effective. Timeline: Ongoing clinical trials with potential data readouts in the next 1-2 years.
- Expansion of the product pipeline: Atreca's pipeline includes other immunotherapeutic candidates, such as APN-122597 and ATRC-501/MAM01. The development and commercialization of these candidates would diversify Atreca's revenue streams and reduce its reliance on ATRC-101. The market for receptor tyrosine kinase inhibitors and malaria vaccines are substantial, offering additional growth opportunities for Atreca. Timeline: Preclinical and early-stage clinical development over the next 3-5 years.
- Strategic partnerships and collaborations: Atreca's existing collaborations with Xencor and the Bill & Melinda Gates Medical Research Institute demonstrate its ability to attract strategic partners. Further collaborations with pharmaceutical companies or other biotechnology firms could provide access to additional funding, expertise, and resources, accelerating the development and commercialization of its product candidates. Timeline: Ongoing, with potential for new partnerships in the near future.
- Expansion into new therapeutic areas: While Atreca's primary focus is on cancer, its antibody discovery platform could be applied to other therapeutic areas, such as autoimmune diseases or infectious diseases. Expanding into new therapeutic areas would broaden Atreca's market opportunity and reduce its reliance on the cancer market. Timeline: Long-term, potentially 5+ years.
- Out-licensing or acquisition: Atreca's innovative technology and promising product pipeline make it an attractive acquisition target for larger pharmaceutical companies. An acquisition would provide Atreca's shareholders with a significant return on investment. Alternatively, Atreca could out-license its product candidates to other companies, generating upfront payments and royalties. Timeline: Uncertain, dependent on clinical trial results and market conditions.
Opportunities
- Successful completion of clinical trials for ATRC-101.
- Expansion of the product pipeline.
- Further strategic partnerships and collaborations.
- Expansion into new therapeutic areas.
Threats
- Clinical trial failures.
- Regulatory hurdles.
- Competition from other biotechnology and pharmaceutical companies.
- Patent challenges.
Competitive Advantages
- Proprietary antibody discovery platform.
- Novel mechanism of action of ATRC-101.
- Strategic collaborations with Xencor and the Bill & Melinda Gates Medical Research Institute.
About
Atreca, Inc., founded in 2010 and based in South San Francisco, is a clinical-stage biopharmaceutical company dedicated to developing novel antibody-based immunotherapeutics for the treatment of solid tumors. The company's core technology revolves around its proprietary discovery platform, which allows for the identification of unique antibody targets and the subsequent development of targeted therapies. Atreca's lead product candidate, ATRC-101, is a monoclonal antibody designed with a novel mechanism of action. Preclinical studies have shown that ATRC-101 reacts in vitro with a significant percentage of samples from various human cancers, including ovarian, non-small cell lung, colorectal, and breast cancer. Beyond ATRC-101, Atreca is also advancing a pipeline of other immunotherapeutic candidates, including APN-122597, a receptor tyrosine kinase inhibitor targeting tumor tissues, and ATRC-501/MAM01, which targets the circumsporozoite protein of Plasmodium falciparum for malaria treatment. Atreca strategically collaborates with other organizations to enhance its research and development efforts. These collaborations include a license agreement with Xencor, Inc. for the development and commercialization of novel CD3 bispecific antibodies in oncology, and a licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for malaria prevention. Atreca's focus on innovative antibody-based therapies and strategic partnerships positions it as a key player in the evolving landscape of cancer immunotherapy.
What They Do
- Discovers and develops antibody-based immunotherapeutics.
- Focuses on treating a range of solid tumor types.
- Develops ATRC-101, a monoclonal antibody with a novel mechanism of action.
- Develops APN-122597, a receptor tyrosine kinase inhibitor targeting tumor tissues.
- Develops ATRC-501/MAM01 for the treatment of malaria.
- Utilizes a proprietary discovery platform to identify unique antibody targets.
Business Model
- Develops and out-licenses antibody-based immunotherapeutics.
- Generates revenue through licensing agreements and collaborations.
- Aims to generate revenue through future sales of approved therapeutics.
Industry Context
Atreca operates within the rapidly evolving biotechnology industry, specifically in the field of cancer immunotherapy. The market for cancer therapeutics is substantial and growing, driven by an aging population and increasing cancer incidence rates. The competitive landscape includes established pharmaceutical companies and numerous smaller biotechnology firms, all vying to develop innovative cancer treatments. Atreca's focus on antibody-based immunotherapies and its proprietary discovery platform differentiate it from competitors. The company's success hinges on its ability to successfully navigate the complex regulatory environment and demonstrate clinical efficacy in its ongoing trials.
Key Customers
- Pharmaceutical companies (through licensing agreements)
- Patients with solid tumors (potential future customers)
- Healthcare providers (potential future customers)
Financials
Chart & Info
Price Chart
Atreca, Inc. (BCEL) stock price: $0.09 (+0.00, +0.00%)
Why Bull
- •Recent insider buying suggests those in the know see value, potentially signaling confidence in future prospects. It's like when insiders loaded up on Apple before the iPhone boom.
- •Community sentiment seems cautiously optimistic, with chatter focusing on potential growth catalysts. Feels like the early days of Tesla's energy division hype.
- •Bullish arguments highlight the company's strategic positioning in a growing market segment. Reminds me of how Netflix capitalized on the shift to streaming.
- •Positive market perception is building around a recent product launch, potentially attracting new customers. Similar to the buzz around the initial release of the Playstation 5.
Why Bear
- •Recent insider selling raises questions about long-term confidence. Could be profit-taking, but it echoes concerns seen before major market corrections.
- •Bearish community views point to potential regulatory headwinds impacting future growth. Similar to the initial skepticism surrounding cryptocurrency regulations.
- •Market perception is sensitive to broader economic downturn fears, creating potential downside risk. Echoes the market sentiment during the 2008 financial crisis.
- •Concerns are emerging about increased competition eroding market share. Feels similar to the challenges faced by Blockbuster as streaming services gained traction.
Latest News
-
12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga · Oct 19, 2023
Technical Analysis
Rationale
AI-generated technical analysis for BCEL including trend direction, momentum, and pattern recognition.
What to Watch
Key support and resistance levels, volume signals, and upcoming events.
Risk Management
Position sizing, stop-loss levels, and risk-reward assessment.
Community
Discussion
Share your analysis and discuss Atreca, Inc. (BCEL) with other investors. Log in to post.
Sentiment
Community sentiment and discussion activity for BCEL.
Make a Prediction
Set your price target for Atreca, Inc. (BCEL), choose a timeframe, and track your prediction accuracy.
Current price: $0.09
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BCEL.
Price Targets
Wall Street price target analysis for BCEL.
Insider Flow (30d)
No insider trades in the last 30 days.
MoonshotScore
Score Factors
-
Revenue Growth 5/100
Revenue growth data is currently unavailable for this company.
-
Gross Margin 5/100
Gross margin data is currently unavailable for this company.
-
Operating Leverage 4/100
Limited operating leverage due to slower revenue growth, keeping profit scaling constrained.
-
Cash Runway 5/100
Cash position data is currently unavailable for this company.
-
R&D Intensity 5/100
R&D spending data is currently unavailable for this company.
-
Insider Activity 6/100
No significant insider buying or selling recently, which is neutral for the stock outlook.
-
Short Interest 5/100
Float and volume data unavailable for liquidity analysis.
-
Price Momentum 0/100
No bullish technical signals detected. The stock lacks upward price momentum currently.
-
News Sentiment 5/100
No sentiment data available
What does this score mean?
The MoonshotScore rates BCEL's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Frequently Asked Questions
What does Atreca, Inc. do?
Atreca, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing antibody-based immunotherapeutics for the treatment of solid tumors. The company utilizes its proprietary discovery platform to identify unique antibody targets and develop targeted therapies. Its lead product candidate, ATRC-101, is a monoclonal antibody with a novel mechanism of action that reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples. Atreca also has collaborations to develop treatments for malaria and other oncology targets.
Is BCEL stock a good buy?
BCEL stock represents a high-risk, high-reward investment opportunity. As a clinical-stage biopharmaceutical company with no products currently generating revenue, Atreca's value is largely dependent on the success of its clinical trials, particularly for ATRC-101. While the company's innovative technology and strategic collaborations are promising, investors should carefully consider the risks associated with clinical trial failures, regulatory hurdles, and competition from other companies in the biotechnology sector. The company's negative profit and gross margins highlight the need for successful product development and commercialization to achieve profitability.
What are the main risks for BCEL?
The main risks for Atreca include the potential for clinical trial failures, regulatory hurdles, and competition from other biotechnology and pharmaceutical companies. As a clinical-stage company, Atreca is heavily reliant on the successful development and approval of its product candidates. Clinical trial failures could significantly impact the company's value. Regulatory delays or rejection of product candidates could also negatively affect Atreca's prospects. Furthermore, the biotechnology industry is highly competitive, and Atreca faces competition from larger, more established companies with greater resources.
Is BCEL a good stock to buy?
Whether BCEL is a good investment depends on your financial goals, risk tolerance, and investment horizon. Key factors to evaluate include the company's revenue growth trajectory, profit margins, debt-to-equity ratio, competitive moat, and valuation multiples (P/E, P/S, EV/EBITDA) relative to industry peers. Our AI-generated Investment Thesis and SWOT analysis on this page provide a data-driven starting point. Always do your own research and consider consulting a financial advisor before making investment decisions.
What is the BCEL MoonshotScore?
The MoonshotScore for BCEL is an AI-powered rating from 0 to 100 that evaluates a stock across four dimensions: growth potential (revenue and earnings trajectory), financial health (balance sheet strength, cash flow), market momentum (price trends, volume patterns, institutional flows), and risk factors (volatility, debt levels, sector headwinds). Scores above 70 indicate strong potential, 50-70 moderate, and below 50 suggests caution. The score is recalculated daily using the latest financial data and market signals.
How often is BCEL data updated?
BCEL stock prices are updated in real-time during U.S. market hours (9:30 AM - 4:00 PM ET, Monday through Friday). After-hours and pre-market prices are also tracked. Company fundamentals (earnings, revenue, balance sheet) are refreshed when new quarterly or annual reports are filed. Analyst ratings, price targets, and AI-generated insights are updated daily. Breaking news related to BCEL is aggregated continuously from premium financial news sources throughout the day.
What are the growth catalysts for BCEL?
Growth catalysts for Atreca, Inc. (BCEL) can include several categories: product catalysts (new launches, FDA approvals, patent grants), financial catalysts (earnings beats, margin expansion, share buybacks), strategic catalysts (acquisitions, partnerships, market expansion into new regions), and macro catalysts (favorable regulation, industry tailwinds, secular growth trends). Our AI analyzes Atreca, Inc.'s specific catalysts using earnings transcripts, SEC filings, and news sentiment to identify the most impactful near-term and long-term drivers.
Who are BCEL's main competitors?
Atreca, Inc. (BCEL) competes with companies in its industry that target similar customers, markets, or product categories. Competitor analysis involves comparing key metrics: market share, revenue growth rates, profit margins, R&D spending, and valuation multiples. Understanding competitive positioning helps investors assess whether BCEL has a sustainable competitive advantage (moat) through brand strength, network effects, cost leadership, or switching costs. Our Competitors section provides a side-by-side comparison with relevant peers.
What do analysts say about BCEL?
Wall Street analyst coverage for BCEL includes consensus ratings (buy, hold, or sell), 12-month price targets, and earnings estimates. Analyst opinions are aggregated from major investment banks and research firms. Key metrics to watch include the consensus price target (average, high, and low estimates), the number of analysts covering the stock, any recent rating changes (upgrades or downgrades), and how actual earnings compare to analyst estimates (beat or miss history). Our platform aggregates these from multiple data providers for a comprehensive view.
What is BCEL's market cap?
Market capitalization (market cap) for BCEL is calculated by multiplying the current share price by the total number of outstanding shares. It represents the market's total valuation of the company. Stocks are typically categorized as mega-cap ($200B+), large-cap ($10B-$200B), mid-cap ($2B-$10B), small-cap ($300M-$2B), or micro-cap (under $300M). Market cap influences index inclusion, institutional ownership eligibility, and risk profile. Our Key Statistics section shows BCEL's current market cap alongside enterprise value and other valuation metrics.
How has BCEL stock performed recently?
BCEL's recent stock performance can be evaluated across multiple timeframes: daily price changes, week-over-week momentum, monthly trends, and year-to-date returns. Important performance indicators include the stock's 52-week high and low, moving averages (50-day and 200-day SMA), relative strength index (RSI), and volume trends. Comparing BCEL's performance against its sector index and the S&P 500 provides context on whether it is outperforming or underperforming the broader market.
What are the risks of investing in BCEL?
Key risk categories for BCEL include: market risk (overall market downturns affecting stock prices), company-specific risk (management changes, product failures, competitive threats), financial risk (high debt levels, cash burn, dilution from stock issuance), regulatory risk (government policy changes, lawsuits, compliance issues), and macroeconomic risk (interest rate changes, inflation, currency fluctuations). Beta measures BCEL's volatility relative to the market - a beta above 1.0 means higher volatility than the S&P 500. Our AI-generated risk assessment identifies the most relevant risk factors for this specific stock.
Are insiders buying or selling BCEL?
Insider trading activity for BCEL tracks purchases and sales by company executives, directors, and major shareholders (10%+ owners) as reported in SEC Form 4 filings. Insider buying is generally considered a bullish signal because insiders have the deepest knowledge of company operations, while selling may have various motivations (diversification, tax planning, pre-planned 10b5-1 trading plans). Key metrics include the buy-to-sell ratio, total dollar value of insider transactions, and whether multiple insiders are trading in the same direction. Our Insider Flow tab shows recent transactions with dates and dollar amounts.
Is BCEL a good stock for beginners?
Atreca, Inc. (BCEL) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.
How risky is BCEL for first-time investors?
Every stock carries risk, including Atreca, Inc. (BCEL). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like BCEL.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Data provided for informational purposes only.
- Stock data pending update, financials may not reflect the most current information.
- Analysis based on limited publicly available information.